SRC and fibrosarcoma: These results are supported by the finding that VEGFR tyrosine kinase inhibitor II, which targets VEGFR1, VEGFR2, c-Kit, and Src, at physiologically relevant doses did not significantly affect the proliferation of 3 myxoid liposarcoma cell lines (including MLS 402 and MLS 1765) or a fibrosarcoma cell line transfected with FUS-CHOP [23].